Company Description
Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems.
The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues.
It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University.
The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021.
Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
| Country | United States |
| Founded | 2017 |
| IPO Date | Jun 30, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 47 |
| CEO | Amro A. Albanna |
Contact Details
Address: 737 N. Fifth Street, Suite 200 Richmond, Virginia 23219 United States | |
| Phone | 909-488-0844 |
| Website | aditxt.com |
Stock Details
| Ticker Symbol | ADTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $9.00 |
| CIK Code | 0001726711 |
| CUSIP Number | 007025109 |
| ISIN Number | US0070256047 |
| Employer ID | 82-3204328 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Amro A. Albanna | Co-Founder, Chairman and Chief Executive Officer |
| Dr. Shahrokh Shabahang D.D.S., M.S., Ph.D. | Co-Founder, Chief Innovation Officer, Secretary and Director |
| Thomas J. Farley CPA | Chief Financial Officer |
| Corinne D. Pankovcin CPA, M.B.A. | Chief Commercialization Officer |
| Rowena Albanna | Chief Operating Officer |
| Jennifer Lee | Director of Human Resources |
| Dr. Dolly B. Tyan Ph.D. | Senior Vice President of Clinical Development ? Transplantation |
| Ge Chen M.D., M.S. | Senior Vice President of Preclinical Research and Discovery |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 18, 2024 | 425 | Filing |
| Jul 18, 2024 | 8-K | Current Report |
| Jul 11, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Jul 9, 2024 | 8-K | Current Report |
| Jul 8, 2024 | 8-K | Current Report |
| Jul 5, 2024 | DEF 14A | Other definitive proxy statements |
| Jul 1, 2024 | PRER14A | Filing |
| Jun 25, 2024 | 8-K | Current Report |
| Jun 21, 2024 | 8-K/A | [Amend] Current report |
| Jun 14, 2024 | 424B3 | Prospectus |